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The Authors Reply: Although there is merit in 
the alternative methods Palomino and colleagues 
mention, elements of which gave rise to the MODS 
assay, the culture time for the Löwenstein–Jensen–
based nitrate reduction assay is three to four times 
that for the MODS assay, with lower sensitivity, 
and as with the direct colorimetric assay, data for 
smear-negative samples are lacking. Unlike MODS 
culture, both techniques involve the potentially 
hazardous opening of mature tuberculosis cul-
tures to add a specific reagent. The thin-layer agar 
method is rapid, but its sensitivity is usually lower 
and its contamination rate higher than those of 
the Löwenstein–Jensen method, and no data on 
drug-susceptibility testing have been published.
In our opinion, MODS culture is actually safer 
than any indirect drug-susceptibility testing meth-
od, since culture amplification and direct drug-
susceptibility testing occur within a closed system: 
the MODS plate is inoculated and then sealed 
within a ziplock bag. It is not manipulated again, 
since all readings, including those for drug-sus-
ceptibility testing, are done through the bag. The 
handling of cultured M. tuberculosis at bacterial 
concentrations thousands of times those of clini-
cal specimens, which is required for secondary 
drug-susceptibility testing, dwarfs the biohazard 
risk associated with sputum-decontamination 
processes common to all culture methods. This 
handling risk is entirely avoided with the MODS 
assay.
Hasan and Irfan did not use ziplock bags, be-
cause this important detail was omitted from 
previous articles on the MODS assay.1-3 We do not 
believe that a MODS laboratory needs to meet 
biosafety level 3 standards. Combining the use by 
laboratory staff of respirators approved by the 
National Institute for Occupational Safety and 
Health and appropriate protective clothing with 
a well-positioned, properly maintained class II 
biologic safety cabinet that recirculates exhausted 
air through a high-efficiency particulate air (HEPA) 
filter into a closed room, should be adequate. With 
respect to rapidly growing mycobacteria, these 
organisms should overgrow MODS plates by day 5, 
a phenomenon not seen with M. tuberculosis.
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Refining Prognosis in Non–Small-Cell Lung Cancer
To the Editor: Potti et al. (Aug. 10 issue)1 apply 
a metagene model to the profiling of non–small-
cell lung cancer (NSCLC) and demonstrate supe-
rior performance in predicting tumor recurrence 
and survival, as compared with a clinical model. 
We believe that the impressively contrasting re-
sults could be partially due to the incompleteness 
of the clinical model the authors used. Classify-
ing NSCLC into squamous-cell carcinoma and ade-
nocarcinoma has not been predictive for prognosis 
in general. However, subtypes of adenocarcino-
ma — bronchioloalveolar carcinoma and mixed 
adenocarcinoma with a bronchioloalveolar compo-
nent, which account for approximately 20% of 
cases of early-stage NSCLC — have a much better 
prognosis than do other subtypes.2 Potti et al. did 
not consider these adenocarcinoma subtypes.
In addition, the literature3 and our recent work 
demonstrate that the histologic grade is a signifi-
cant predictor of both tumor recurrence and sur-
vival,4 and there is a high correlation between 
histologic features and gene-expression profiles.5 
Our work also shows that incorporating the ade-
nocarcinoma subtype and histologic grade into 
clinical models would provide a prediction very 
similar to that of a well-validated, 50-gene panel 
for survival.5
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To the Editor: Potti et al. mention that adjuvant 
chemotherapy is beneficial in patients with stages 
IB, II, or IIIA NSCLC. We think the question re-
garding the benefit of adjuvant chemotherapy in 
patients with stage IB disease is still open. Analy-
sis of the Cancer and Leukemia Group B (CALGB) 
9633 trial, which was presented at the 2006 meet-
ing of the American Society of Clinical Oncology, 
showed no survival benefit at 5 years in patients 
with stage IB disease who received adjuvant che-
motherapy.1
These results mirror the findings of two pre-
vious trials, which did not show any survival ben-
efit of adjuvant chemotherapy for patients with 
stage IB disease. The Adjuvant Navelbine Inter-
national Trialist Association (ANITA) study2 and 
the National Cancer Institute of Canada’s JBR.10 
trial3 also showed no significant survival advan-
tage with the administration of adjuvant chemo-
therapy for patients with stage IB disease.
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To the Editor: Potti et al. report on a model con-
sisting of nine metagenes (the dominant factors 
in a cluster of genes) for predicting the recurrence 
of lung cancer. Such a model can influence treat-
ment decisions substantially. We reasoned that it 
should be possible to replicate the predictive abil-
ity of these metagenes independently, regardless of 
the microarray platform or biostatistical meth-
ods used.
Of the 133 genes in the 9 metagenes, 120 were 
represented in our data set (Operon-HuV2) of re-
sected lung tumors from patients with stage I, II, 
or III disease (51 squamous-cell tumors and 48 
adenocarcinomas), classified according to whether 
the patient was disease-free for more than 3 years 
or had a recurrence within 1.5 years. We gener-
ated a principal component score for each meta-
gene and classified the tumors using axis-parallel 
decision trees with leave-one-out cross-validation. 
The metagenes predicted recurrence with an ac-
curacy of 53% for squamous-cell tumors and 75% 
for adenocarcinomas. In contrast, the mean ac-
curacy of 100 random permutations was 49% 
(P<0.05).
Our lower overall predictive accuracy, as com-
pared with that of Potti et al., may be due to the 
profiling of incomplete metagenes on nonidentical 
microarray platforms. Nevertheless, in this “real 
world” test, the nine metagenes retained the abil-
ity to predict recurrence in an independent cohort 
of adenocarcinomas, attesting to the potential of 
this model for clinical use.
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The authors reply: Although pathological dif-
ferentiation of lung tumors has been shown to be 
beneficial in understanding the underlying biol-
ogy, very few subtypes are considered to be stan-
dard prognostic indicators, with the exception of 
the bronchioloalveolar phenotype. The study cited 
by Sun and Yang1 describes hazard ratios of ap-
proximately 2.0 for undifferentiated tumors. In 
contrast, the odds ratios for the genomic predic-
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tor of recurrence in our study were 16.1 and 35.0 
in the two independent validation cohorts. Thus, 
although inclusion of the histologic grade may en-
hance the predictive capability of a model, it is 
unlikely to have a significant effect on the differ-
ence seen between the prognostic abilities of clini-
copathological variables and genomic data.
Singh and Dhindsa are correct in stating that 
the recent results of the CALGB 9633 trial suggest 
that there was no absolute survival benefit for 
patients with stage IB disease who were treated 
with adjuvant chemotherapy.2 This result was re-
ported after our article went to press. Although 
this finding does not affect the results of our 
study, it does suggest that the clinical benefit of 
a refined prognosis could be extended to all pa-
tients with stage I disease, rather than just those 
with stage IA disease. Indeed, Kaplan–Meier sur-
vival analysis of all patients with stage I disease, 
stratified as high risk or low risk on the basis of 
the gene-expression model, revealed a subgroup 
with significantly poorer survival (Fig. 1), a result 
similar to that seen when the analysis was re-
stricted to patients with stage IA disease.
Larsen et al. suggest that independent repli-
cation of the genes that were identified in our 
analysis should be possible, regardless of the 
microarray platform and biostatistical methods 
used. We disagree. The platform will clearly affect 
absolute measures of gene activity, and the meth-
od of analysis that is used to generate a predictive 
model will also have a substantial effect on the 
selection of genes. In addition, many studies now 
point to the complexity of cancer phenotypes and 
the capacity of multiple gene sets to serve as pre-
dictive models.3 The critical question in any of 
these studies is not the specific set of genes 
developed to predict an outcome but, rather, the 
ability to replicate any given model in multiple 
sample sets. We demonstrated replication of our 
original finding in three independent data sets.
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Figure 1. Kaplan–Meier Survival Analysis of 138 Patients 
with Stage I Non–Small-Cell Lung Cancer.
On the basis of a gene-expression model, 55 patients 
were classified as having high-risk tumors, and 83 as 
having low-risk tumors.
Survivors of Childhood Cancer
To the Editor: Oeffinger et al. (Oct. 12 issue)1 
describe the late effects of the treatment of child-
hood cancer. Pelvic irradiation and alkylating 
agents increase the risks of infertility, gonadal 
dysfunction, and premature ovarian failure. The 
child’s sex and age at the time of treatment influ-
ence these risks.2
Advances in the freezing of gonadal tissue and 
oocytes3,4 can improve the chances that a survi-
vor of childhood cancer will become a parent. 
Future research by the Childhood Cancer Survi-
vor Study (CCSS) should address the problem of 
infertility, which is important to survivors of 
childhood cancer.5
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